In the last few months, Memorial Sloan Kettering has worked to contain the fallout from intensifying scrutiny over several potential conflicts of interest, including its executives’ financial ties to drug and healthcare companies.
In one instance, one of its top researchers and former CMO José Baselga, MD, PhD, failed to disclose significant financial ties to the drug industry and other healthcare companies in more than 100 research articles. A partnership with an artificial intelligence startup, founded by three insiders at the cancer center, also came under fire.
The outside review, conducted by law firm Debevoise & Plimpton, found that in multiple instances top officials violated or skirted their own policies. In addition, the firm found that when hospital leaders had ties to outside companies, those potential conflicts of interest were not critically examined and were instead discussed ad hoc. Researchers were often unaware that senior executives had financial stakes in the outcomes of their studies, the review found.
Memorial Sloan Kettering executives were debriefed on the outside review at a staff meeting this week. After acknowledging flaws in its oversight of potential conflict of interest violations, the leadership team announced it would undertake an extensive overhaul of policies.
The outside review is just one of the several steps taken by the cancer center in the wake of reports that surfaced last year that several top executives and board members had profited from relationships with pharmaceutical companies.
More articles on leadership and management:
Philadelphia hospital to lay off 175 employees amid financial troubles
Democrats request closer look at CMS administrator’s contract awards
House Democrats unveil healthcare bill: 8 things to know
